医学
食品药品监督管理局
药品审批
药品
药理学
环境卫生
作者
Xiaofang Zhang,Carl C. Peck,Yaning Wang,Thomas D. Szucs,Wan Sun,Xue Bai,Siyu Chen,Fengzhi Wang,Yangfeng Wu
出处
期刊:BMC Medicine
[BioMed Central]
日期:2024-12-18
卷期号:22 (1): 587-587
被引量:1
标识
DOI:10.1186/s12916-024-03800-6
摘要
The number of drug-indication pairs receiving AA increased sharply during 2015-2016 to 2019-2020 but fell in 2021-2022. Meanwhile, the strength of clinical evidence supporting FDA's AAs appeared to decline from 2015 to 2020 but seems to have improved in 2021-2022. Measures should be taken to further improve the strength of evidence in Accelerated Approvals.
科研通智能强力驱动
Strongly Powered by AbleSci AI